Fujifilm to Invest $200 Million to Expand Cell Therapy Development, Manufacturing Capabilities
By Ronnie Harui
Fujifilm plans to invest $200 million in two subsidiaries in the U.S. to expand its global cell therapy contract development and manufacturing capabilities, the Japanese conglomerate said Tuesday.
The investment is earmarked for the new headquarters of Fujifilm Cellular Dynamics in Wisconsin and the California site of Fujifilm Diosynth Biotechnologies, Fujifilm said in a statement. The investment will enable Fujifilm to support the expanding cell therapy market, which is expected to grow by more than 30% a year from an estimated $3.3 billion in fiscal 2022, it added.
Cell therapies are a promising treatment with the ability to augment, repair and replace human biology, including organs, tissues and cells, Fujifilm said.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
December 04, 2023 23:14 ET (04:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations